August 5, 2022
The University of Cincinnati's John Byrd, MD, was featured in a Cure article on the FDA's approval of the tablet form of the drug Calquence to treat multiple blood cancers.
May 1, 2024
Yahoo News featured comments from the University of Cincinnati's Rekha Chaudhary in a story about rising rates of diagnoses and deaths from colorectal cancers among young people.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
October 16, 2023
A collaborative team led by University of Cincinnati, University of North Carolina and Duke University researchers is studying how specific cancers and treatments affect patients' risk of stroke.
March 26, 2024
A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.
May 29, 2024
University of Cincinnati Cancer Center experts will present research on ovarian and blood cancer trials, the link between poor sleep and cancer-related cognitive impairment, and an innovative youth education program at the American Society of Clinical Oncology annual meeting 2024 in Chicago.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
October 24, 2022
University of Cincinnati researchers presented results from the first-in-human trial of FLASH radiotherapy at the ASTRO 2022 annual meeting, with data suggesting FLASH may hold promise as a potential treatment for tough-to-kill tumors.
March 22, 2024
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
September 7, 2022
GEN News highlighted recent University of Cincinnati and Cincinnati Children's Hospital Medical Center research on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments.